Pharmaceutial Pricing and Reimbursement in China

Decision Resources
June 29, 2009
31 Pages - SKU: DECR2303161
License type:
Table of Contents Related Reports
Countries covered: China

Introduction

With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third largest in the world in 2011. A radical healthcare reform package recently unveiled by the government will more than double public healthcare expenditures from 2009 to 2011. For biopharmaceutical companies competing in China, future success will depend on a clear understanding of the implications of these reforms.

Questions Answered in This Report
  • More than 1 billion of China's 1.3 billion residents now have some form of government-sponsored health
    • insurance. Which are the most important public health insurance programs? What level of benefi ts do these programs offer? What changes are planned for the near future?
  • Prices for international branded drugs in China are generally comparable to prices in some European markets.
    • How do Chinese prices compare with prices in the United States? Which kinds of drugs have prices close to, or higher than, U.S. prices?
  • Hospitals are the dominant distribution channel for prescription drugs in China. Why do hospitals play such an important role in the healthcare system and the pharmaceutical market? How does the government plan to exercise stricter control over hospital prescribing in the future?
  • In the future, a drug's reimbursement prospects are likely to depend heavily on inclusion in a new national essential medicines list. How extensive is this list likely to be? How will the healthcare system procure and use drugs on this list?
Scope
  • Regulatory structure: key policy decision makers in the Chinese healthcare system.
  • Organization and funding of the healthcare system: historical perspective, health insurance, organization
    • of healthcare provision.
  • Pharmaceutical pricing: historical pricing procedures, standard pricing procedures, premium pricing,
    • centralized drug tenders, international price comparison.
  • Reimbursement and cost containment: drug reimbursement, price cuts.
  • Outlook and implications for the pharmaceutical industry: changes to the health insurance system, investment in healthcare facilities and professionals, improved quality and range of healthcare services for patients, new system of hospital funding, overhaul of the pharmaceutical supply system, challenges and opportunities for drug manufacturers.
Please note, the PDF e-mail from publisher version of this report is for a global site license.


More China Manufacturing, Packaging & Detailing Reports

China's Pharmaceutical Industry 2011 by China Research and Intelligence Co., Ltd.
This report describes the general development of China’s pharmaceutical industry in aspects of investment, production, sales, import & export, major prices and operations. ...

Research Report on Chinese Human Vaccine Industry, 2012 by China Research and Intelligence Co., Ltd.
The research object of the report is human vaccine apart from animal vaccine. Vaccination is the most economical, effective, safe and convenient way to prevent ...

China Pharmaceutical Industry Research and Forecast to 2016 by AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms ...

Freedonia Focus on Pharmaceutical Packaging: China by Freedonia Focus
This report discusses pharmaceutical packaging in China for the years 2005 and 2010, with forecasts for 2015. Topics covered include overview of products; market overview; ...

China’s Guidebook for Pharmaceutical Patent Protection by Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Juice – China – a snapshot (2010) by Mintel - Snapshots
Juice in China by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. The report covers packaged ...

See all reports like this >>

 

Share this report


Other tasks

 
 

Research Assistance

Ask a question
 

Related Markets


Manufacturing, Packaging & Detailing Reports

 
 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!